SAN DIEGO, May 14 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc.
(Nasdaq: RDEA) today announced that preclinical data will be presented on
the Company's lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119,
at Digestive Disease Week (DDW) 2008 in San Diego.

The oral presentation details are as follows:

Date/Time: Tuesday, May 20, 2008 at 3:30 p.m. Pacific Time

Abstract Title: RDEA119, a Potent and Highly Selective MEK Inhibitor

Ameliorates Murine Colitis

Session Title: Novel Therapeutic Agents in Experimental Colitis

Location: 28DE: San Diego Convention Center

About Ardea Biosciences

Ardea Biosciences, Inc. of San Diego, California, is a biotechnology
company focused on the discovery and development of small-molecule
therapeutics for the treatment of HIV, cancer and inflammatory diseases,
including gout. We have four drug candidates in clinical trials and several
others in preclinical development and discovery. Our most advanced drug
candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor
(NNRTI), which is in a Phase 2a study for the treatment of HIV. We have
evaluated our second generation NNRTI, RDEA427, for the treatment of HIV in
a human micro-dose pharmacokinetic study and have selected it as a
development candidate. We are also investigating RDEA806 for the treatment
of gout. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1
study in advanced cancer patients, as well as in a Phase 1 study in normal
healthy volunteers for the treatment of inflammatory diseases. We have
evaluated our second generation MEK inhibitor, RDEA436, for the treatment
of cancer and inflammatory diseases in a human micro-dose pharmacokinetic
study, and have selected it as a development candidate. In addition to the
foregoing clinical programs, we are investigating other drug candidates in
earlier stages of preclinical development and discovery.

Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such forward-looking
statements. Such statements include, but are not limited to, statements
regarding: sufficiency of cash resources and our goals, including the
expected properties and benefits of RDEA806, RDEA427, RDEA119, RDEA436 and
our other compounds and the results of preclinical, clinical and other
studies. Risks that contribute to the uncertain nature of the
forward-looking statements include: risks related to the outcome of
preclinical and clinical studies, risks related to regulatory approvals,
delays in commencement of preclinical and clinical studies, and costs
associated with internal development and business development activities.
These and other risks and uncertainties are described more fully in our
most recently filed SEC documents, including our Annual Report on Form 10-K
and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors."
All forward-looking statements contained in this press release speak only
as of the date on which they were made. We undertake no obligation to
update such statements to reflect events that occur or circumstances that
exist after the date on which they were made.

(Date:9/21/2017)... ... September 21, 2017 , ... Vixiar ... executive, engineering and manufacturing functions to The LaunchPort™ Accelerator at the City Garage ... full range of manufacturing and business services to its Residents. , Vixiar ...

(Date:9/21/2017)... Philadelphia PA and London UK (PRWEB) , ... ... ... from DrugDev , a QuintilesIMS company, who enable the world’s most progressive ... learned from over 2,000 clinical trials at top pharma and biotech events in ...

(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...